-
ArticlePublication 2008Community and Patient Values for Preventing Herpes Zoster
In this 2008 article, the authors report on a survey to assess the value individuals …
In this 2008 article, the authors report on a survey to assess the value individuals place on preventing herpes zoster. The Zoster Vaccine Live (ZVL) was recommended for routine use in adults aged ≥60 years. Members of the population (“community members”, n= 527), patients with shingles (n= 382) or post-herpetic neuralgia (PHN, n = 137) completed an internet or telephone survey to assess the value they place on preventing herpes zoster. The authors used standard…
Preferences/Values | Health Outcomes | Culture/Society | Health/Medicine | North America -
ArticlePublication 2007Measuring Health Preferences for Use in Analyses of Interventions in Children
Valuing the health of children for cost-utility or cost-benefit analysis is more challenging than valuing …
Valuing the health of children for cost-utility or cost-benefit analysis is more challenging than valuing adult health. Young children cannot conceptualize value, they are not responsible for their own decision making, and proxies may not fully understand the child perspective. Moreover illness in children may affect parent/caregiver health and quality of life, further complicating the measurement of value associated with a change in a child’s health status.This paper reviews the most common approaches (QALYs and willingness-to-pay)…
Preferences/Values | Health Outcomes | Infectious Diseases | Child/Nutrition | North America | Europe -
ArticlePublication 2008Potential Cost-Effectiveness of Vaccination against Herpes Zoster and Post-Herpetic Neuralgia
This 2008 Canadian study assessed the cost effectiveness of the Zoster Vaccine Live (ZVL) vaccine …
This 2008 Canadian study assessed the cost effectiveness of the Zoster Vaccine Live (ZVL) vaccine against herpes zoster (HZ) and post-herpetic neuralgia (PHN). The authors used a cohort model to estimate the burden of HZ and the cost-effectiveness of HZ vaccination from a ministry of health perspective using Canadian population-based data. They examined different ages at vaccination and conducted probabilistic sensitivity analysis.There are about 130,000 new cases of HZ, 17,000 cases of PHN and 20 deaths…
Preferences/Values | Cost-Effectiveness Analysis | Dynamic Transmission | Infectious Diseases | Health/Medicine | North America -
GuidelinesPublication 2016Decision Models in Clinical Preventive Services Recommendations
The U.S. Preventive Services Task Force (USPSTF) develops evidence-based recommendations about preventive care based on …
The U.S. Preventive Services Task Force (USPSTF) develops evidence-based recommendations about preventive care based on comprehensive systematic reviews of the best available evidence. Decision models provide a complementary, quantitative approach to support the USPSTF as it deliberates about the evidence and develops recommendations for clinical and policy use. This article describes the rationale for using modeling, an approach to selecting topics for modeling, and how modeling may inform recommendations about clinical preventive services.
Decision Analysis | Health Outcomes | Evidence Synthesis | Mathematical Models | Health Systems | Policy/Regulation | Health/Medicine | North America -
ArticlePublication 2016Cost-Effectiveness of a Herpes Zoster Vaccination Program among the French Elderly People
This study reports on a cost-effectiveness analysis of herpes zoster (HZ) vaccines among the elderly …
This study reports on a cost-effectiveness analysis of herpes zoster (HZ) vaccines among the elderly in France. Starting vaccination in individuals aged 65, 70 and 75 years old appears more cost-effective than vaccination for beginning vaccination at age 60, with a cost-effectiveness ratio between 30,000 and 35,000 euros per quality-adjusted-life year (QALY) gained for the 65 and 70-year age groups versus 54,500 euros for the age 75 group. These results largely contributed to the recommendation…
Cost-Effectiveness Analysis | Infectious Diseases | Economics/Finance | Health/Medicine | Europe -
ArticlePublication 2015Cost-Effectiveness of Herpes Zoster Vaccine for Persons Aged 50 Years
This article reports on a cost-effectiveness analysis of the original herpes zoster (HZ) vaccine (ZVL) …
This article reports on a cost-effectiveness analysis of the original herpes zoster (HZ) vaccine (ZVL) that at the time of this study was approved for persons age 50+. The authors used a Markov model to simulate adults aged 50 years over a lifetime from a societal perspective; outcomes included the number of HZ and postherpetic neuralgia (PHN) cases prevented and the incremental cost per quality-adjusted life-year (QALY) saved. Their focus was on the cost effectiveness…
Cost-Effectiveness Analysis | State-Transition | Infectious Diseases | Health Systems | Health/Medicine | North America -
ArticlePublication 2013Vaccination against Herpes Zoster and Postherpetic Neuralgia in France: A Cost-Effectiveness Analysis
This article reports on a cost-effectiveness analysis of the original herpes zoster vaccine (ZVL) for …
This article reports on a cost-effectiveness analysis of the original herpes zoster vaccine (ZVL) for the 65 year + population in France. The authors compared vaccinating all adults over 65 years versus adults from 70-79 years, over their lifetimes, from a third-party payer perspective. French-specific data were combined with results from clinical studies and international quality-of-life-based (EuroQol 5D) utilities from the literature. Results showed incremental cost-effective ratios d between €9513 and €12,304 per quality-adjusted life…
Preferences/Values | Cost-Effectiveness Analysis | State-Transition | Infectious Diseases | Health/Medicine | Europe -
ArticlePublication 2015Distribution of Health Effects and Cost-Effectiveness of Varicella Vaccination
This article reports on an analysis of the impact of universal childhood varicella vaccination on the …
This article reports on an analysis of the impact of universal childhood varicella vaccination on the incidence of herpes zoster (HZ) using dynamic transmission modelling and cost-effectiveness analyses. Scenarios that are considered differ by whether or not immune boosting is included, and whether or not reactivation of vaccine virus is possible. The authors report that health effects of varicella vaccination in scenarios with immune boosting are unevenly distributed: cohorts born just before introduction of vaccination and…
Preferences/Values | Cost-Effectiveness Analysis | Dynamic Transmission | Infectious Diseases | Health/Medicine | Europe -
ReviewPublication 2015Humanistic, Economic and Societal Burden of Herpes Zoster in Europe
This review provides documentation and critical appraisal of published data concerning the humanistic, economic and …
This review provides documentation and critical appraisal of published data concerning the humanistic, economic and societal burden of herpes zoster (HZ) in Europe. From a review of 1619 abstracts, 53 eligible articles, were identified which reported data concerning healthcare resource use (n = 38), direct costs (n = 20), indirect costs (n = 16), total costs (n = 10) and impact on health-related quality of life (HRQoL) (n = 21).The findings indicate that postherpetic neuralgia…
Preferences/Values | Cost-Effectiveness Analysis | Costing Methods | Health Outcomes | Infectious Diseases | Europe -
ReviewPublication 2013Systematic Review of the Cost Effectiveness of Herpes Zoster Vaccination
This review summarized the herpes zoster (HZ) vaccination cost effectiveness literature, consisting of 11 studies …
This review summarized the herpes zoster (HZ) vaccination cost effectiveness literature, consisting of 11 studies Most studies evaluated the cost effectiveness of universal HZ vaccination in adults aged 50 years or 60 years and older and all studies calculated costs per QALY. The costs per QALY gained and the incremental cost-effectiveness ratio (ICER) differed depending on the age at vaccination, duration of vaccine efficacy, cost of vaccine course, and economic perspective. All but one of…
Preferences/Values | Cost-Effectiveness Analysis | Infectious Diseases | Clinical Care | Economics/Finance | Health/Medicine | North America -
Working PaperPublication 2017Cost-Effectiveness Analysis of Adjuvanted Subunit Vaccine for Prevention of Herpes Zoster
Herpes zoster (HZ) develops in up to 50% of unvaccinated individuals who live to 85 …
Herpes zoster (HZ) develops in up to 50% of unvaccinated individuals who live to 85 years of age, accounting for more than 1 million cases of HZ annually in the United States. A live attenuated vaccine (LAV) for HZ is U.S. FDA approved for persons 50 years or older, though CDC Advisory Committee on Immunization Practices (ACIP) recommendations are only for persons beginning at age 60 years. LAV efficacy at preventing HZ is ~70% for…
Cost-Effectiveness Analysis | Mathematical Models | Infectious Diseases | Economics/Finance | Health/Medicine | North America